Multi-million dollar investment allows for continued clinical studies on
the Delivra™ Technology
RICHMOND HILL, ON, June 13, 2013 /CNW Telbec/ - Pharmax™, a leading-edge, comprehensive line of professional grade nutraceutical
products announces today its Topical PRO™ series of creams use the innovative clinically studied Delivra™ trans-dermal
technology from Delivra Inc. Following a recent multi-million dollar
investment, this unique technology and specific Pharmax™ products will
be the subject of a large scale research project spearheaded by Dr.
Joseph Gabriele, the developer of the Delivra™ technology and a close
and long-time collaborator of Pharmax™.
The Delivra™ trans-dermal technology takes advantage of established
interactions between natural substances and human cellular and nerve
tissues to address pain management without the side effects associated
with typical interventions.
Recently, the Atlantic Canada Opportunities Agency (ACOA) Atlantic Innovation Fund announced an investment of close to $3 million to support a
comprehensive research project for the Delivra™ technology. This
significant investment clearly validates further development of the
already strong existing technology. The objective of the new research
program is to develop innovative topical creams for the treatment of
common inflammatory conditions.
"In 2011, we were first-to-market exclusively for the healthcare
practitioner segment with novel natural topical creams using the
Delivra delivery system," said Yves Yau, Head of the Pharmax™ brand.
We are proud of this latest advancement that emphasizes our ongoing
commitment to provide only the highest quality, research-driven
products offering cutting-edge ingredients. The new research project
and our close collaboration with Dr. Joseph Gabriele will continue to
place Pharmax™ at the forefront of trans-dermal technology."
The Delivra™ technology is found in Pharmax™ Topical PRO™ products - Pharmax™ Varicose, Pharmax™ Rebuild, Pharmax™ Heal, Pharmax™ Nerve, Pharmax™ Relief and Pharmax™ Fibro.
Pharmax™ offers a complete line of clinically-proven, safe and
effective, natural products available exclusively through health care
professionals. For further information on Pharmax™ products powered by
Delivra™, visit http://www.seroyal.com/brands/pharmax.
Pharmax™, a trusted brand of Atrium Innovations Inc. (TSX: ATB), is a
leading-edge, comprehensive line of professional grade nutraceuticals
products built upon a 15 year research-driven, evidence-based
scientific foundation. Pharmax™ is continuously looking at improving
or adding efficacious products to the range of nutritional products
available to the healthcare practitioner. For additional information,
please visit www.seroyal.com/brands/pharmax.
ABOUT ATRIUM INNOVATIONS
Atrium Innovations Inc. (TSX: ATB) is a globally recognized leader in the development,
manufacturing, and commercialization of innovative, science-based
natural health products which are distributed in more than 35
countries. The Company owns healthcare practitioner and specialized
retail product brands that are at the forefront of science, innovation
and education. Atrium has over 1,100 employees and operates seven
manufacturing facilities complying with current Good Manufacturing
Practices. Additional information is available at www.atrium-innovations.com.
ABOUT DELIVRA INC.
Headed by Dr. Joseph Gabriele, Delivra Inc. is comprised of a team of
innovative scientists and medical professionals who have come together
to develop natural, safe and effective medications, using a
revolutionary new delivery system, Delivra™. Delivra™ is a patented,
proprietary organic compound discovered by Dr. Gabriele that harnesses
the body's own processes to ensure a greater depth of penetration in
transporting healing substances. Delivra™ can be used to safely and
effectively deliver a wide range of medications directly through the
For further information: